Research tagged [neonatology]

Management of Phenobarbital-Resistant Neonatal Seizures in Hypoxic-Ischemic Encephalopathy: A Community Peer-Reviewed Clinical Consensus

Background: Neonatal seizures, particularly in the context of hypoxic-ischemic encephalopathy (HIE), represent a significant neurological emergency. Despite phenobarbital being the established first-line anticonvulsant, a substantial proportion of neonates exhibit refractory seizures, necessitating the judicious selection of second-line agents. Optimal management strategies for these challenging cases, including appropriate antiepileptic drug (AED) dosing, electroencephalographic monitoring targets, and pharmacokinetic considerations during therapeutic hypothermia, remain areas of ongoing clinical discussion. Methods: This paper synthesizes a peer-reviewed clinical discussion initiated on the tachyDx platform. A clinical scenario involving a 3-day-old term neonate with HIE Grade II experiencing phenobarbital-resistant seizures during therapeutic hypothermia was presented. Two verified physician experts provided detailed responses, which subsequently garnered 49 community peer votes. Results: Levetiracetam was identified as the preferred second-line agent over phenytoin, citing its comparable efficacy to phenobarbital in some studies and a more favorable side effect profile in neonates. Recommended levetiracetam dosing included a 40-60 mg/kg intravenous load followed by 10-30 mg/kg/day maintenance in divided doses. Consensus indicated a goal of electrographic seizure freedom on amplitude-integrated electroencephalography (aEEG) if achievable without excessive sedation, with a threshold for escalating therapy defined as continuous seizure activity exceeding 50% of a 1-hour epoch. However, caution was advised against over-treatment of isolated, brief electrographic events. Therapeutic hypothermia was noted to reduce hepatic metabolism by approximately 25%, impacting phenobarbital levels, while levetiracetam, being primarily renally cleared, was less affected, though mild reductions in glomerular filtration rate were acknowledged. Conclusions: This expert consensus provides practical guidance for managing phenobarbital-resistant neonatal seizures in HIE. Levetiracetam emerges as a favored second-line option, with specific dosing and aEEG monitoring strategies outlined. The critical influence of therapeutic hypothermia on AED pharmacokinetics necessitates careful monitoring and dose adjustments. These findings underscore the importance of individualized, evidence-informed approaches to optimize neurodevelopmental outcomes.